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Abstract 
The objective of this report is to explore the balance between serum and synovial fluid 
levels of interleukin (IL)-18 in children with juvenile idiopathic arthritis (JIA). 
Blood samples were obtained from 81 children with JIA and 18 control children. 
Synovial fluid samples were collected from 16 children with oligoarticular JIA. 
Concentrations of IL-18 were determined using commercial kit. 
Patients with systemic JIA had higher serum levels of IL-18 than patients with other 
forms of JIA or control children, both during the active (median, range: 6240, 1600 – 
78750 pg/mL) and inactive (1615, 513 – 3270 pg/mL) phase of disease (ANOVA, 
P<0.05). Levels of IL-18 in sera of children with oligoarticular JIA (255, 89 – 4342 
pg/mL) were similar to the respective synovial fluid levels (217, 89 – 1245 pg/mL). 
Serum levels of IL-18 were proportional to the erythrocyte sedimentation rate and levels 
of C-reactive protein, but inversely proportional to the haemoglobin levels.  
IL-18 appears to be an important mediator of systemic JIA, while it seems of a lesser 
relevance in pathogenesis of other JIA forms. Therefore, inhibition of IL-18 might be a 
base for a successful biologic therapy of systemic JIA.  
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Introduction 
 
Juvenile idiopathic arthritis (JIA) comprises a heterogeneous group of clinical conditions 
with unknown aetiology. Pathogenesis of JIA is not fully understood but it seems that, in 
genetically susceptible individuals, various triggering factors (e.g. trauma, joint infection, 
hormone levels) may lead to the immune dysbalance and subsequent articular and 
systemic manifestations [1]. 
Several aspects of immune dysregulation in JIA have been described, including alteration 
of regulatory T cell numbers, as well as abnormal chemokine and cytokine production, 
especially IL-1β, IL-6 and TNF-α [2-5]. Among the cytokines, IL-18 should also be 
particularly interesting with respect to the pathogenesis of JIA. IL-18 stimulates a variety 
of inflammatory responses, enhances proliferation and activity of T cells and NK cells, 
and shifts helper T cell balance towards Th1 response [6,7]. We suspected that IL-18 is 
not only a prominent mediator of JIA, but that different forms of JIA could be associated 
with different levels of IL-18 as well. Therefore, to get an insight into role of IL-18 in 
JIA, we aimed to explore the serum levels of IL-18 both during the active and quiescent 
phases of the disease. 
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Materials and methods 
 
A total of 81 children (50 girls, 31 boys; median age 7, range 1 – 19 years), consecutively 
admitted at the Division of Paediatric Rheumatology between December 2002 and April 
2005 with the diagnosis of JIA, were included in the present study. Out of those 81 
children, 31 had oligoarticular JIA, 33 had polyarticular JIA, and 17 had the systemic 
form of JIA, in accordance to the ILAR criteria [8]. In addition, we included a control 
group of 18 randomly selected children (9 girls, 9 boys; median age 10.5, range 2 – 16 
years), who were admitted at the Division due to non-inflammatory conditions, during the 
same period. The study was approved by the Ethics Committee of the Zagreb University 
School of Medicine. 
Peripheral blood was obtained from each patient in both active phase of disease and, 
later, in clinical remission, which we, according to Walace and her co-workers, referred 
to as “inactive on medication” [9]. The criteria for inactive phase on medication were 
following: no active arthritis, fever, rash, hepatosplenomegaly, generalized 
lymphadenopathy, active uveitis, and serositis; normal erythrocyte sedimentation rate and 
C-reactive protein levels; during a minimum of six continuous months while receiving 
medication. In addition, synovial fluid samples were collected at the same time as the 
peripheral blood from 16 patients with the oligoarticular form of JIA. Routine laboratory 
tests were performed at the Department of Clinical Laboratory Diagnostics. Serum and 
synovial fluid concentrations of IL-18 were determined using commercially available kit, 
following the manufacturers’ recommendations (Human IL-18 ELISA Kit, Medical & 
Biological Laboratories Co., Naka-ku Nagoya, Japan). 
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Data were summarised using median and range. The groups were compared by ANOVA, 
followed by Student-Newman-Keuls post hoc test, while the bivariate relationships were 
analysed using Spearman’s ρ. Comparisons within the group (i.e. active phase vs. 
inactive on medication) were performed using Student’s t-test for dependent samples. 
The α-level was set at 0.05. MedCalc for Windows (MedCalc Software, Mariakerke, 
Belgium) was used for the analyses. 
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Results 
 
During the active phase of JIA, children with systemic form of disease had higher serum 
levels of IL-18 than children with oligoarticular or polyarticular form (ANOVA and 
Student-Newman-Keuls post hoc test, F3,95 = 9.282, P < 0.001) (Table I). The same 
pattern was observed in the inactive phase: children with systemic JIA had the highest 
serum levels of IL-18 (ANOVA and Student-Newman-Keuls post hoc test, F3,91 = 54.651, 
P < 0.001). Serum levels of IL-18 in children with systemic JIA during the remission 
were significantly lower compared to the levels found in the active phase (Student’s t-test 
for dependent samples, t15 = -5.197, P < 0.001). On the other hand, synovial 
concentrations of IL-18 in 16 patients with oligoarticular JIA (median, range: 206, 23 – 
832 pg/mL; n = 16) did not differ significantly from serum levels of IL-18 in the same 
patients (median, range: 217, 89 – 1245 pg/mL) (Student’s t-test, P = 0.555). 
The serum levels of IL-18 in the active phase of all patients correlated well with several 
laboratory tests, commonly used to evaluate a status of JIA patient: erythrocyte 
sedimentation rate (ρ = 0.33, P = 0.001), C-reactive protein level (ρ = 0.39, P < 0.001), 
haemoglobin level (ρ = -0.35, P < 0.001), haematocrit (ρ = -0.37, P < 0.001), platelet 
count (ρ = 0.28, P = 0.014), and α2-globulin levels (ρ = 0.35, P = 0.002). Some 
associations were found to be significant even during the remission, although they were 
weaker when compared to the active phase: haemoglobin level (ρ = -0.22, P = 0.038), 
haematocrit (ρ = -0.25, P = 0.020), and platelet count (ρ = 0.25, P = 0.033). 
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Discussion 
 
Results of the present study point to the increased levels of IL-18 in the systemic form of 
JIA. Although the elevation of IL-18 levels has been reported in children with systemic 
JIA and patients with adult-onset Still’s disease [10,11], we have clearly shown that the 
serum levels of IL-18 in systemic JIA remain high even during the inactive phase on 
medication. In addition, the serum concentrations of IL-18 correlated well with several 
laboratory indicators of inflammation, both during active and, although to the lesser 
extent, inactive on medication phase of JIA. Taken together, the findings indicate that IL-
18 could contribute to the pathogenesis of the inflammatory process in systemic JIA, not 
only during the exacerbation, but also during the clinically silent phase of the disease. On 
the other hand, it could be inferred that IL-18 is not a major mediator of oligoarticular or 
polyarticular JIA. 
Furthermore, our study was, to the best of our knowledge, the first to determine the 
articular concentrations of IL-18 in active phase of JIA, at the beginning, or at the early 
stage of disease. As IL-18 is involved in the pathogenesis of articular damage in 
rheumatoid arthritis [12] and the elevated expression of IL-18 mRNA was described in 
affected joints of JIA patients [13], we expected to find abundant levels of IL-18 in the 
synovial fluid of the inflamed joints. Surprisingly, the serum levels of IL-18 in children 
with oligoarticular JIA were comparable to the synovial levels of the same cytokine, 
indicating that the pathogenesis of arthritis in oligoarticular JIA is probably mediated by 
other tissue factors, but not IL-18. 
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We also have to note certain limitations of our work. First, number of patients with 
systemic JIA was relatively small. Furthermore, we focused on only one cytokine, while 
it is know that interactions between cytokine and chemokines are very complex and to 
fully understand the role of IL-18 in pathogenesis of JIA, relationship between IL-18 and 
other mediators should be explored. 
In spite of limitations, the data presented in the manuscript indicate that IL-18 could be 
involved in the systemic inflammation within the course of JIA. Increased levels of IL-18 
during the remission on medication of systemic JIA might imply that the inflammatory 
process is still active, although the patients’ erythrocyte sedimentation rates and C-
reactive protein levels were within the limits of the normal findings. Thus, monitoring of 
IL-18 levels could prove out to be a useful prognostic tool. Furthermore, our results 
suggest that IL-18 could be an excellent target for biologic therapy of systemic JIA. 
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Table I. Serum concentrations of interleukin-18 (median, range) (pg/mL) in 81 children 
with juvenile idiopathic arthritis (JIA) and 18 control children, during the active phase 
and in inactive phase on medication. 
 
group n active phase inactive on medication 
oligoarticular JIA 31 255 (89 – 4342) 201 (76 – 842) 
polyarticular JIA 33 271 (126 – 3690) 208 (83 – 996) 
systemic JIA 17 6240 (1600 – 78750)* 1615 (513 – 3270)*† 
control 18 315 (176 – 439) 
* P<0.001 vs. the other groups during the same phase, ANOVA and Student-
Newman-Keuls test 
† P<0.001 vs. active phase, Student’s t-test for dependent samples 
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